



(86) **Date de dépôt PCT/PCT Filing Date:** 2013/10/31
 (87) **Date publication PCT/PCT Publication Date:** 2014/05/08
 (85) **Entrée phase nationale/National Entry:** 2015/04/21
 (86) **N° demande PCT/PCT Application No.:** US 2013/067695
 (87) **N° publication PCT/PCT Publication No.:** 2014/070983
 (30) **Priorité/Priority:** 2012/10/31 (US61/720,838)

(51) **Cl.Int./Int.Cl. C07C 311/29** (2006.01),
A61K 31/16 (2006.01), **A61K 31/165** (2006.01),
A61K 31/18 (2006.01), **A61K 31/196** (2006.01),
A61K 31/21 (2006.01), **A61K 31/216** (2006.01),
A61K 31/40 (2006.01), **A61K 31/404** (2006.01),
A61K 31/42 (2006.01), **A61K 31/4245** (2006.01),
A61K 31/427 (2006.01), ...
 (71) **Demands/ Applicants:**
 THE REGENTS OF THE UNIVERSITY OF MICHIGAN,
 US;
 EASTERN MICHIGAN UNIVERSITY, US
 (72) **Inventeurs/Inventors:**
 LAWRENCE, DANIEL A., US;

(54) **Titre : INHIBITEURS DE L'ACTIVATEUR 1 DU PLASMINOGENE ET LEURS PROCEDES D'UTILISATION**
 (54) **Title: PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITORS AND METHODS OF USE THEREOF**

(57) **Abrégé/Abstract:**

The invention relates to plasminogen activator- 1 (PAI-1) inhibitor compounds and uses thereof in the treatment of any disease or disorder associated with elevated PAI-1. The invention includes, but is not limited to, the use of such compounds to prevent or reduce thrombosis and fibrosis, to promote thrombolysis, and to modulate lipid metabolism and treat diseases or disorders associated with elevated PAI-1, cholesterol, or lipid levels.

(51) **Cl.Int./Int.Cl. (suite/continued)** *C07C 233/15* (2006.01), *C07C 233/56* (2006.01), *C07C 235/34* (2006.01), *C07C 235/46* (2006.01), *C07C 243/10* (2006.01), *C07C 259/06* (2006.01), *C07D 207/48* (2006.01), *C07D 209/34* (2006.01), *C07D 249/08* (2006.01), *C07D 277/34* (2006.01), *C07D 417/04* (2006.01)

(72) **Inventeurs(suite)/Inventors(continued):** EMAL, CORY, US; REINKE, ASHLEY, US; LI, SHIH-HON, US; WARNOCK, MARK, US; ABERNATHY, GREGORY, US

(74) **Agent:** SMART & BIGGAR